MedTrace Logo

Prevalence of Kidney Injury in Patients With HCV Treated With Sofuspovir Containing DAA Therapy

NCT04267458 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2020-02-12

No results posted yet for this study

Summary

this study aims is to investigate the occurrence of AKI during antiviral therapy, defined as an increase of 0.3 mg/dL or 50% at least in serum creatinine level when compared with baseline values or more than a 25% reduction in (eGFR) when compared with baseline eGFR in Egyptian patients.In addition to evaluate the change in insulin resistance value after treating patients from HCV.

Conditions

  • Investigate the Renal Effect of DAAs on Egyption Patients After Completion of Treatment

Interventions

OTHER

evaluation of sofuspovir containing DAA regien expected insult on kidney

to use different kidney biomarkers to evaluate acute kidney damage after using sofuspovir containing DAA regimen in treatment of HCV

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Dalia Zaafar, PhD · Lecturer of pharmacology and toxicology

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2020-04-30
Completion
2020-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04267458 on ClinicalTrials.gov